

Author index to volume 9

- Aamdal S. *See* Semb KA, 797
- Aapro MS *et al.* Gemcitabine—a safety review, 191
- Abbas FM *et al.* Cost, quality of life and outcome measures in ovarian cancer, 859
- Ackermann T. *See* Kurbacher CM, 51
- Aggarwal BB. *See* Singh S, 703
- Aggarwal SK. *See* Muenchen HJ, 93
- Agostino I. *See* Neri B, 599
- Akinaga S. *See* Kanazawa J, 653
- Akiyama N. *See* Kizu R, 167
- Al-Gharably NM. *See* Badary OA, 809
- Al-Katib A. *See* Mohammad RM, 149
- Al-Shabanah OA. *See* Badary OA, 809
- Alama A. *See* Cagnoli M, 603
- Aleksandrak K *et al.* Antimitotic activity of diaryl compounds with structural features resembling combretastatin A-4, 545
- Allain P. *See* Gamelin E, 223
- Allen M *et al.* The importance of stabilization as an endpoint in the treatment of metastatic colorectal carcinoma: recent quality of life studies, 783
- Almatchy VP. *See* Mohammad RM, 149
- An D. *See* Orlowski S, 551
- Anderson R. *See* Wolff JEA, 803
- Ando E. *See* Yamashita F, 399
- Andreoli F. *See* Neri B, 599
- Andreotti PE. *See* Kurbacher CM, 51
- Antimi M. *See* Kleisbauer J-P, 387
- Arnoldi E. *See* Zaniboni A, 295
- Ashizawa T *et al.* Antitumor activity of KW-2170, a novel pyrazoloacridine derivative, 263
- Augustine K. *See* Kudelka AP, 621
- Azevedo MC. *See* Kleisbauer J-P, 387
- Badary OA *et al.* Effect of Cremophor EL on the pharmacokinetics, antitumor activity and toxicity of doxorubicin in mice, 809
- Balachandran R *et al.* The potent microtubule-stabilizing agent (+)-discodermolide induces apoptosis in human breast carcinoma cells—preliminary comparisons to paclitaxel, 67
- Balmes H. *See* Kleisbauer J-P, 387
- Bamberg M. *See* Schiebe ME, 433
- Barbieri F. *See* Cagnoli M, 603
- Barni S. *See* Zaniboni A, 295
- Barret J-M *et al.* DNA repair mechanisms associated with cellular resistance to antitumor drugs: potential novel targets, 105
- Bartolini P. *See* Neri B, 599
- Bauer JA. Synthesis, characterization and nitric oxide release profile of nitrosylcobalamin: a potential chemotherapeutic agent, 239
- Becagli P. *See* Messori A, 491
- Beck WT. *See* Dolan ME, 437
- Bedikian AY. *See* Prager TC, 515
- Beex LVAM. *See* Bruning PF, 419; *also* Paridaens R, 29
- Beijnen JH. *See* Herben VMM, 411; *also* Nannan Panday VR, 665; *also* Rosing H, 587; *also* Sparreboom A, 1
- Belchradek J Jr. *See* Orlowski S, 551
- Belka C. *See* Schiebe ME, 433
- Benjapibal M *et al.* Docetaxel and cyclophosphamide induced remission in platinum and paclitaxel refractory ovarian cancer, 577; *also* Kudelka AP, 621
- Benner SE. *See* Hoff PM, 497
- Bernard S. *See* Socinski MA, 611
- Bertram J *et al.* Elevated expression of S100P, CAPl and MAGE 3 in doxorubicin-resistant cell lines: comparison of mRNA differential display reverse transcription-polymerase chain reaction and subtractive suppressive hybridization for the analysis of gene expression, 311
- Bhattacharya RK. *See* Rao KN, 727
- Bleiberg H *et al.* Continuing the fight against advanced colorectal cancer: new and future treatment options, 18; *also* Tropisetron in the prevention of acute and delayed nausea and vomiting over six courses of emetogenic chemotherapy, 773; *also* Gerard B, 301
- Blumberg N. *See* Griggs JJ, 925
- Boffetta P *et al.* Cisplatin-DNA adducts and protein-bound platinum in blood of testicular cancer patients, 125
- Boisdron-Celle M. *See* Gamelin E, 223
- Bokemeyer C. *See* Hartmann JT, 427
- Bolognesi A. *See* Zaniboni A, 295
- Bonfrer JMG. *See* Bruning PF, 419
- Borsi JD. *See* Paál K, 765
- Braguer D. *See* Carles G, 209
- Brenne U. *See* Kurbacher CM, 51
- Breton C *et al.* Bcl-2 expression correlates with apoptosis induction but not loss of clonogenic survival in small lung cancer cell lines treated with etoposide, 751
- Briand C. *See* Carles G, 209
- Brienza S. *See* Gamelin E, 223; *also* Gerard B, 301
- Brouwer KLR. *See* Socinski MA, 611
- Brown RE *et al.* Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients, 899
- Bruckner HW. *See* Kurbacher CM, 51
- Bruning PF *et al.* Vorozole (R83842) in the treatment of postmenopausal advanced breast cancer: relationship of serum levels of vorozole and clinical results (a study of the EORTC Breast Cancer Cooperative Group), 419
- Bruynseels J. *See* Bruning PF, 419
- Bruzzo C. *See* Cagnoli M, 603
- Bryan WJ. *See* Cristofanilli M, 779
- Budman DR *et al.* *In vitro* evaluation of synergism or antagonism with combinations of new cytotoxic agents, 697
- Bugat R. *See* Jozan S, 229
- Buijt I *et al.* Costs of intensive treatment and follow-up of patients with multiple myeloma, 889
- Bult A. *See* Rosing H, 587
- Buyse M. *See* Bleiberg H, 773
- Cadman TB. *See* Wurz GT, 181
- Cafaggi S. *See* Mandys V, 659; *also* Viale M, 457
- Cagnoli M *et al.* Synthesis and biological activity of gold and tin compounds in ovarian cancer cells, 603
- Cailleux A. *See* Gamelin E, 223
- Calabro A. *See* Budman DR, 697
- Canetta R. *See* Hoff PM, 497
- Cardarelli N. *See* Cascinu S, 307
- Carles G *et al.* The effect of combining antitubulin agents on differentiated and undifferentiated human colon cancer cells, 209
- Carmichael J *et al.* Use of granisetron in patients refractory to previous treatment with antiemetics, 381
- Cascinu S *et al.* Phase II study of paclitaxel in pretreated advanced gastric cancer, 307
- Cassar G. *See* Gamet-Payrasatre L, 141
- Catalano G. *See* Cascinu S, 307
- Catalin J. *See* Leca F-R, 503

Author index to volume 9

- Čemažar M *et al.* Intratumoral cisplatin administration in electrochemotherapy: antitumor effectiveness, sequence dependence and platinum content, 525
- Cerna C. *See* Soda H, 327
- Chang AY-C. *See* Cristofanilli M, 779
- Chang K-H. *See* Lai Y-L, 77
- Chang W-C. *See* Chen J-S, 393
- Charnsangavej C. *See* Vasuratna A, 283
- Chase EM. *See* Miller TP, 135
- Chatterjee A. *See* Choudhaur SK, 825
- Chen J-S *et al.* Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas, 393
- Chen J. *See* Pu Y-S, 733
- Chen M-L. *See* Lai Y-L, 77
- Chen Y. *See* Perchellet EM, 565
- Chen Y-J. *See* Lai Y-L, 77
- Cheng A-L. *See* Pu Y-S, 733
- Choi EJ. *See* Choi S-U, 157; *also* Choi S-U, 255
- Choi S-U *et al.* Reversal of multidrug resistance by novel verapamil analogs in cancer cells, 157; *also* The bisbenzylisoquinoline alkaloids, tetrandine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein, 255
- Choudhaur SK *et al.* Reversal of resistance against doxorubicin by a newly developed compound, oxalyl bis(N-phenyl)hydroxamic acid *in vitro*, 825
- Chung C-H. *See* Lai Y-L, 77
- Clary A *et al.* Transcriptional down-regulation of *c-myc* expression in an erythroleukemic cell line, K562, and its doxorubicin-resistant variant by two topoisomerase II inhibitors, doxorubicin and amsacrine, 245
- Cnaan A. *See* Janss AJ, 641
- Conrad CA. *See* Kudelka AP, 405
- Contu A. *See* Kleisbauer J-P, 387
- Côté S *et al.* Demethylation by 5-aza-2'-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor β gene in human colon carcinoma cells, 743
- Courtade M. *See* Jozan S, 229
- Cree IA. *See* Kurbacher CM, 51
- Cristofanilli M *et al.* Phase II study of adozelesin in untreated metastatic breast cancer, 779
- Csáki C. *See* Paál K, 765
- Cunningham D. *See* Allen M, 783
- Cupissol D. *See* Carmichael J, 381
- Cvitkovic E. *See* Gamelin E, 223
- Daikeler T. *See* Hartmann JT, 427
- Dalton WS. *See* Miller TP, 135
- Davidson K *et al.* Mitoguazone induces apoptosis via a p53-independent mechanism, 635
- Day BW. *See* Balachandran R, 67
- de Belder K. *See* Paridaens R, 675
- De Keyser P. *See* Bleiberg H, 773
- DeGregorio MW. *See* Wurz GT, 181
- Di Leo A. *See* Gerard B, 301
- di Salle E. *See* Paridaens R, 675
- Diamond AM. *See* Dolan ME, 437
- Diergarten K. *See* Klaassen U, 203
- Dolan ME *et al.* Effects of 1,2-naphthoquinones on human tumor cell growth and lack of cross-resistance with other anticancer agents, 437
- Dolzan V. *See* Cemazar M, 525
- Dorr R. *See* Miller TP, 135
- Doyle C. *See* Patnaik A, 869
- Doyle E. *See* Rosing H, 587
- Dranitsaris G. Treatment of non-Hodgkin's lymphoma, 879
- Dubbelman RC. *See* Nannan Panday VR, 665
- Dwivedi C *et al.* Effects of oil-soluble organosulfur compounds from garlic on doxorubicin-induced lipid peroxidation, 291
- Eberhardt W. *See* Klaassen U, 203
- Edwards CL. *See* Benajipal M, 577; *also* Kudelka AP, 405; *also* Kudelka AP, 621; *also* Vasuratna A, 283; *also* Verschraegen CF, 36
- Ekelund S *et al.* Microphysiometry: new technology for evaluation of anticancer drug activity in human tumor cells *in vitro*, 531
- Elmazar MMA. *See* Badary OA, 809
- Ende K. *See* Verschraegen CF, 36
- Engel H. *See* Kurbacher CM, 51
- Engineer FN. *See* Dwivedi C, 291
- Eriguchi M. *See* Kizu R, 167
- Ertan AK. *See* Villena-Heinsen C, 557
- Esposito M. *See* Mandys V, 659; *also* Viale M, 457
- Farnhammer C. *See* Villena-Heinsen C, 557
- Fattman CL. *See* Hasinoff BB, 465
- Ferencz T. *See* Paál K, 765
- Fernex B. *See* Gerard B, 301
- Fichtinger-Schepman AMJ. *See* Boffetta P, 125
- Forman A. *See* Kudelka AP, 405
- Formento JL. *See* Harstrick A, 625
- Fossa SD. *See* Boffetta P, 125
- Freedman RS. *See* Kudelka AP, 405; *also* Verschraegen CF, 36
- Friedrich M. *See* Villena-Heinsen C, 557
- Frydman B. *See* Dolan ME, 437
- Fu Q. *See* Zhu Z, 685
- Fukuda H. *See* Yamashita F, 399
- Fukumori K. *See* Yamashita F, 399
- Fukushima M *et al.* Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil, 817
- Galeani A. *See* Leca F-R, 503
- Gamelin E *et al.* Determination of unbound platinum after oxaliplatin administration: comparison of currently available methods and influence of various parameters, 223
- Gamet-Payrasat L *et al.* Selective cytostatic and cytotoxic effects of glucosinolates hydrolysis products on human colon cancer cells *in vitro*, 141
- Garbiras BJ. *See* Dolan ME, 437
- García-Girón A. *See* Kleisbauer J-P, 387
- Gasc N. *See* Gamet-Payrasat L, 141
- Gehl J *et al.* Enhancement of cytotoxicity by electroporation: an improved method for screening drugs, 319
- Gemelli MT. *See* Neri B, 599
- Gerard B *et al.* Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer, 301
- Geromichalos G. *See* Liakopoulou-Kyriakides M, 175
- Gil Th. *See* Gerard B, 301
- Gilster TJ. *See* Kurbacher CM, 51
- Giordani P. *See* Cascinu S, 307
- Giovannella BC. *See* Verschraegen CF, 36
- Gips M. *See* Lyass O, 100
- Goedhals L. *See* Krzakowski M, 593
- Gomez L. *See* Soda H, 327
- Gomi K. *See* Ashizawa T, 263
- Gonzales A. *See* Harstrick A, 625
- Gonzalez P. *See* Socinski MA, 611
- Gradishar WJ. *See* Cristofanilli M, 779
- Graham E. *See* Krzakowski M, 593
- Grant SG. *See* Balachandran R, 67
- Graziano F. *See* Cascinu S, 307
- Griggs JJ *et al.* Recombinant erythropoietin and blood transfusions in cancer chemotherapy-induced anemia, 925
- Grothey A. *See* Kudelka AP, 405
- Grove W. *See* Kudelka AP, 405
- Guan J-Y. *See* Pu Y-S, 733
- Gullaksen N. *See* Semb KA, 797
- Hadfield JA. *See* Aleksandrak K, 545
- Hagiwara A *et al.* Therapeutic effects of 5-fluorouracil microspheres on peritoneal carcinomatosis induced

- by Colon 26 or B-16 melanoma in mice, 287; *also* A pilot study of fibroscopy-guided local injection of anti-cancer drugs bound to carbon particles for control of rectal cancer, 363
- Hamada J-i. *See* Kuramitsu Y, 88; *also* Kuramitsu Y, 739
- Hanske M. *See* Klaassen U, 203
- Hara Y. *See* Sakamoto S, 351
- Harstrick A *et al.* Comparison between short and long exposure to 5-fluorouracil in human gastric and colon cancer cell lines: biochemical mechanism of resistance, 625; *also* Hartmann JT, 427; *also* Klaassen U, 203; *also* Klaassen U, 359
- Hartmann JT *et al.* Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer, 427
- Hasenbaur A. *See* Kudelka AP, 405
- Hasinoff BB *et al.* The one-ring open hydrolysis intermediates of the cardioprotective agent dexrazoxane (ICRF-187) do not inhibit the growth of Chinese hamster ovary cells or the catalytic activity of DNA topoisomerase II, 465
- Hatty S. *See* Aapro MS, 191
- Hayakawa K. *See* Kizu R, 167
- Hendlish A. *See* Gerard B, 301
- Herben VMM *et al.* Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer, 411
- Hiddemann W. *See* Bertram J, 311
- Hilkens PHE. *See* Pronk LC, 759
- Hill BT. *See* Barret J-M, 105
- Hillebrand MJX. *See* Nannan Panday VR, 665
- Hillner BE. Review of cost-effectiveness assessments of chemotherapy in adjuvant and advanced breast cancer, 843
- Hirahara N. *See* Takeda H, 715
- Hirano T. *See* Nakajima S, 539
- Hirata Y. *See* Hagiwara A, 363
- Hirvikoski PP. *See* Kumpulainen EJ, 131
- Hiwasa T *et al.* Enhancement of chemosensitivity toward anticancer drugs by high expression of caspase-1 in NIH 3T3 cells, 82
- Hoff PM *et al.* UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer, 497
- Hoffmann W. *See* Schiebe ME, 433
- Hortobagyi GN. *See* Cristofanilli M, 779
- Horváth J. *See* Pál K, 765
- Hosokawa M. *See* Kuramitsu Y, 88; *also* Kuramitsu Y, 739; *also* Matsushita K, 273; *also* Matsushita K, 343
- Houston SJ. *See* Paridaens R, 29
- Hsieh C-Y. *See* Pu Y-S, 733
- Hua DH. *See* Perchellet EM, 565
- Hubbard GB. *See* Wurz GT, 181
- Hubert A. *See* Lyass O, 100
- Hudson I. *See* Herben VMM, 411
- Huijgens PC. *See* Buijt I, 889
- Hulstaert F. *See* Bleiberg H, 773
- Hutton J. *See* Brown RE, 899
- Hyon S-h. *See* Hagiwara A, 287
- Ikada Y. *See* Hagiwara A, 287
- Ingvar C. *See* Semb KA, 797
- Intini C. *See* Zaniboni A, 295
- Israel M. *See* Lothstein L, 58
- Izbicka E. *See* Davidson K, 635; *also* Soda H, 327
- Jan Y-Y. *See* Chen J-S, 393
- Janss AJ *et al.* Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines, 641
- Jeffers S. *See* Safta T, 511
- Johansson RT. *See* Kumpulainen EJ, 131
- John LM. *See* Dwivedi C, 291
- Joly F. *See* Krzakowski M, 593
- Jozan S *et al.* Cytotoxic effect of interferon- α 2a in combination with *all-trans* retinoic acid or cisplatin in human ovarian carcinoma cell lines, 229
- Jung H-P. *See* Choi S-U, 255
- Jung N-P. *See* Choi S-U, 157
- Kaldor J. *See* Boffetta P, 125
- Kamm YJL *et al.* 5-Fluorouracil in colorectal cancer: rationale and clinical results of frequently used schedules, 371
- Kanazawa J *et al.* The relationship between the antitumor activity and the ribonucleotide reductase inhibitory activity of (*E*)-2'-deoxy-2'-(fluoromethylene) cytidine, MDL 101,731, 653
- Kanz L. *See* Hartmann JT, 427
- Kato O. *See* Yamashita F, 399
- Kato T. *See* Fukushima M, 817
- Kavanagh JJ. *See* Benjapibal M, 577; *also* Kudelka AP, 405; *also* Kudelka AP, 621; *also* Vasuratna A, 283; *also* Verschraegen CF, 36
- Keizer HJ. *See* Boffetta P, 125; *also* Carmichael J, 381
- Kellaway J. *See* Prager TC, 515
- Kidani Y. *See* Kizu R, 167
- Kim H-S. *See* Choi S-U, 255
- Kim J *et al.* Pharmacokinetics of recombinant human interferon- α 2a combined with 5-fluorouracil in patients with advanced colorectal carcinoma, 689
- Kim K-H. *See* Choi S-U, 157; *also* Choi S-U, 255
- Kim S. *See* Choi S-U, 255
- Kizu R *et al.* Significance of water solubility in the gastrointestinal absorption of trans-bis(*n*-valerate) 1*R*,2*R*-cyclohexanediamine(oxalato)platinum(IV), an orally active platinum complex, and its analogs, 167
- Klaassen U *et al.* Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer, 203; *also* Paclitaxel plus ifosfamide in advanced ovarian cancer: results of a phase I study, 359
- Kleisbauer J-P *et al.* Granisetron plus methylprednisolone for the control of high-dose cisplatin-induced emesis, 387
- Klijn JGM. *See* Bruning PF, 419; *also* Paridaens R, 29
- Kneba M. *See* Bertram J, 311
- Kobayashi H. *See* Kuramitsu Y, 739; *also* Kuramitsu Y, 88
- Kobayashi M. *See* Matsushita K, 273; *also* Matsushita K, 343
- Koester S. *See* Davidson K, 635
- Kollmannsberger C. *See* Hartmann JT, 427
- Koopman FJ. *See* Nannan Panday VR, 665
- Korn M. *See* Klaassen U, 203
- Kortsaris AH. *See* Liakopoulou-Kyriakides M, 175
- Koss-Twardy SG. *See* Kim J, 689
- Kraft SL. *See* Perchellet EM, 565
- Krebs B. *See* Wolff JEA, 803
- Kreis W. *See* Budman DR, 697
- Krikorian A. *See* Gamelin E, 223
- Krzakowski M *et al.* A multicenter, double-blind comparison of i.v. and oral administration of ondansetron plus dexamethasone for acute cisplatin-induced emesis, 593
- Kudelka AP *et al.* Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian cancer, 405; *also* Gemcitabine after bone marrow transplantation for refractory juvenile granulosa cell tumor, 621; *also* Benjapibal M, 577; *also* Vasuratna A, 283; *also* Verschraegen CF, 36
- Kudo H. *See* Sakamoto S, 351
- Kufe DW. *See* Cristofanilli M, 779

Author index to volume 9

- Kumpulainen EJ *et al.* Cancer risk after adjuvant chemo- or chemohormonal therapy of breast cancer, 131
- Kuramitsu Y *et al.* A new anti-metastatic drug, ND-2001, inhibits lung metastases in rat hepatoma cells by suppressing haptotaxis of tumor cells toward laminin, 88; *also* ND-2001 suppresses lung metastasis of human renal cancer cells in athymic mice, 739; *also* Matsushita K, 343
- Kurbacher CM *et al.* Use of an *ex vivo* ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer, 51
- Kurbacher JA. *See* Kurbacher CM, 51
- Kusaba T. *See* Yamashita F, 399
- Kuschak TI. *See* Hasinoff BB, 465
- Kuwa K. *See* Sakamoto S, 351
- Kyriakidis DA. *See* Liakopoulou-Kyriakides M, 175
- Ladesich JB. *See* Perchellet EM, 565
- Lai M-K. *See* Pu Y-S, 733
- Lai Y-L *et al.* Induction of apoptosis in human leukemic U937 cells by tetrandrine, 77
- Lam KS. *See* Miller TP, 135
- Langenaeken C. *See* Paridaens R, 29
- Lanzalone S. *See* Paridaens R, 675
- Larra F. *See* Gamelin E, 223
- Larrue A. *See* Clary A, 245
- Larsson R. *See* Ekelund S, 531
- Lawrence P. *See* Socinski MA, 611
- Lawrence R. *See* Soda H, 327
- Le Corroller A-G *et al.* The economic evaluation of hematopoietic growth factors in high-dose chemotherapy, 917
- Leboul A. *See* Gamelin E, 223
- Leca F-R *et al.* Pharmacokinetic-pharmacodynamic relationships between pirarubicin exposure and hematotoxicity: clinical application using only one blood sample, 503
- Lee B-H. *See* Choi S-U, 157
- Lee C-O. *See* Choi S-U, 157; *also* Choi S-U, 255
- Lees J. *See* Krzakowski M, 593
- Lehnert SM. *See* Yapp DTT, 791
- Letrent SP. *See* Socinski MA, 611
- Levov C. *See* Janss AJ, 641
- Li D-K. *See* Zhu Z, 685
- Li Y-Q. *See* Matsushita K, 343
- Liakopoulou-Kyriakides M *et al.* Antiproliferative activity of synthetic tetrapeptides, analogs of ASI phytotoxin, towards cancer cell lines, 175
- Liao Q. *See* Zhu Z, 685
- Liau C-T. *See* Chen J-S, 393
- Lin Y-C. *See* Chen J-S, 393
- Lloyd DK. *See* Yapp DTT, 791
- Lobelle J-P. *See* Paridaens R, 675
- Lochon I. *See* Jozan S, 229
- Lossos A. *See* Lyass O, 100
- Lothstein L *et al.* Cytotoxicity and intracellular biotransformation of *N*-benzyladriamycin-14-valerate (AD 198) are modulated by changes in 14-O-acyl chain length, 58
- Lu K. *See* Harstrick A, 625
- Lu S-H. *See* Pu Y-S, 733
- Lumeau S. *See* Gamet-Payrasatre L, 141
- Luque A. *See* Kleisbauer J-P, 387
- Lyass O *et al.* Cisplatin-induced non-convulsive encephalopathy, 100
- Mäenpää JU. *See* Wurz GT, 181
- Mallmann PK. *See* Kurbacher CM, 51
- Mandys V *et al.* Neurotoxic effect of cisplatin and the cisplatin-procaine complex DPR studied in organotypic cultures of chick embryonic dorsal root ganglia, 659
- Marcellini M. *See* Cascinu S, 307
- Marchiset-Leca D. *See* Leca F-R, 503
- Martin C. *See* Aapro MS, 191
- Marton IJ. *See* Dolan ME, 437
- Massuti-Sureda B. *See* Kleisbauer J-P, 387
- Mastronardi L *et al.* Tamoxifen as a potential treatment of glioma, 581
- Mathieu-Boue A. *See* Jozan S, 229
- Matsushita K *et al.* ONO-4007 induces specific anti-tumor immunity mediated by tumor necrosis factor- α , 273; *also* Combination therapy of active hexose correlated compound plus UFT significantly reduces the metastasis of rat mammary adenocarcinoma, 343
- Matsuzawa A. *See* Kizu R, 167
- McGown AT. *See* Aleksandrak K, 545
- McIntyre S. *See* Prager TC, 515
- McQuade B. *See* Krzakowski M, 593
- Mendoza J. *See* Singh S, 703
- Menichetti ET. *See* Cascinu S, 307
- Messori A *et al.* Treatments for newly diagnosed ovarian cancer: analysis of survival data and cost-effectiveness evaluation, 491; *also* Pharmacoeconomic profile of taxanes in advanced ovarian cancer, 909
- Mette E. *See* Semb KA, 797
- Meyers CA. *See* Kudelka AP, 405
- Meyn RE. *See* Breton C, 751
- Miklavčić D. *See* Čemazar M, 525
- Milačić R. *See* Čemazar M, 525
- Milano G. *See* Harstrick A, 625
- Miller LL. *See* Cristofanilli M, 779
- Miller TP *et al.* A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease, 135
- Milliez J. *See* Carmichael J, 381
- Mir LL. *See* Gehl J, 319
- Mir LM. *See* Orłowski S, 551
- Mitamura T. *See* Sakamoto S, 351
- Moatti J-P. *See* Le Corroller A-G, 917
- Mohammad RM *et al.* Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma, 149
- Momparler RL. *See* Côté S, 743
- Morikawa K. *See* Kuramitsu Y, 88; *also* Kuramitsu Y, 739
- Mudd PN Jr. *See* Socinski MA, 611
- Muenchen HJ *et al.* Immune system activation by cisplatin and its analog polyplat: an *in vitro* and *in vivo* study, 93
- Muggia FM. *See* Safra T, 511
- Müller C. *See* Hartmann JT, 427; *also* Klaassen U, 203
- Müller K. *See* Kurbacher CM, 51
- Muranishi S. *See* Hagiwara A, 287
- Nagarajan B. *See* Venkatesan PV, 449
- Naito S. *See* Kuramitsu Y, 739
- Nakagaware A. *See* Hiwasa T, 82
- Nakajima S *et al.* Therapeutic effect of interstitial photodynamic therapy using ATX-S10(Na) and a diode laser on radio-resistant SCCVII tumors of C3H/He mice, 539
- Nakanishi T. *See* Kizu R, 167
- Nannan Panday VR *et al.* Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer, 665
- Natelson EA. *See* Verschraegen CF, 36
- Neri B *et al.* Results of leucovorin and doxifluridine oral regimen in the treatment of metastatic colorectal cancer, 599
- Nightingale CH. *See* Zhu Z, 685
- Nio Y. *See* Takeda H, 715
- Noble A. *See* Leca F-R, 503
- Nooij M. *See* Bruning PF, 419; *also* Paridaens R, 29
- Nooijen WJ. *See* Sparreboom A, 1
- Novelli F. *See* Cagnoli M, 603
- Nygren P. *See* Ekelund S, 531
- Obara M. *See* Matsushita K, 343
- Ohiro Y. *See* Matsushita K, 343
- Ohshimo H. *See* Fukushima M, 817
- Ohtani H. *See* Takeda H, 715
- Okabe M. *See* Ashizawa T, 263; *also* Kanazawa J, 653
- Okayasu I. *See* Sakamoto S, 351
- Olas B *et al.* Modulation of cisplatin toxicity in blood platelets by glutathione depletion, 473

- Omori H. *See* Takeda H, 715
- Orlowski S *et al.* Antimetastatic effects of electrochemotherapy and of histoincompatible interleukin-2-secreting cells in the murine Lewis lung tumor, 551
- Ornati G. *See* Paridaens R, 675
- Osmundsen K. *See* Semb KA, 797
- Ossenkopppele GJ. *See* Buijt I, 889
- Oza AM. *See* Patnaik A, 869
- Paál K *et al.* Effect of etoposide on the pharmacokinetics of methotrexate *in vivo*, 765
- Palfner K. *See* Bertram J, 311
- Pantalone D. *See* Neri B, 599
- Pantazis P. *See* Singh S, 703
- Papazisis KT. *See* Liakopoulou-Kyriakides M, 175
- Paridaens R *et al.* Vorozole (RivizorTM): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure, 29; *also* Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study, 675; *also* Bruning PF, 419
- Park S-H. *See* Choi S-U, 157; *also* Choi S-U, 255
- Park W-K. *See* Choi S-U, 255
- Pascha KP. *See* Wolff JEA, 803
- Passe SM. *See* Kim J, 689
- Pastrone I. *See* Viale M, 457
- Patel IH. *See* Kim J, 689
- Patnaik A *et al.* Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost, 869
- Pawlicki M. *See* Krzakowski M, 593
- Pazdur R. *See* Hoff PM, 497; *also* Kim J, 689
- Pellecchia C. *See* Viale M, 457
- Pellier P. *See* Kleisbauer J-P, 387
- Perchellet EM *et al.* Antitumor activity of tricyclic pyrone analogs, a new synthetic class of microtubule de-stabilizing agents, in the murine EMT-6 mammary tumor cell line *in vitro*, 565
- Perchellet J-P. *See* Perchellet EM, 565
- Peretz T. *See* Lyass O, 100
- Pernice ML. *See* Neri B, 599
- Petit T. *See* Davidson K, 635
- Pettit GR. *See* Mohammad RM, 149
- Phillips PC. *See* Janss AJ, 641
- Piccart MJ. *See* Bruning PF, 419; *also* Paridaens R, 29
- Polli A. *See* Paridaens R, 675
- Poppenborg H. *See* Wolff JEA, 803
- Pourquier P. *See* Clary A, 245
- Prager TC *et al.* Evaluation of ocular safety: tirapazamine plus cisplatin in patients with metastatic melanomas, 515
- Pronk LC *et al.* Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel, 759
- Pu Y-S *et al.* Megestrol acetate antagonizes cisplatin cytotoxicity, 733
- Pukkala E. *See* Kumpulainen EJ, 131
- Punt CJA. *See* Kamm YJL, 371
- Puzzilli F. *See* Mastronardi L, 581
- Radomski KM. *See* Socinski MA, 611
- Raju U. *See* Singh S, 703
- Ranjan P *et al.* Murine peritoneal macrophages treated with cisplatin and interferon- γ undergo NO-mediated apoptosis via activation of an endonuclease, 333
- Rao KN *et al.* β -Carboline-benzoquinolizidine alkaloid deoxytubulosine inhibits thymidylate synthase activity in leukemic leukocytes from patients with chronic myeloblastic leukemia and acute lymphoblastic leukemia, 727
- Rapoport B. *See* Krzakowski M, 593
- Raymond E. *See* Soda H, 327
- Rietjens IMCM. *See* Kamm YJL, 371
- Robert J. *See* Clary A, 245; *also* Gamelin E, 223
- Rodrigues PJ. *See* Lothstein L, 58
- Rollin P. *See* Gamet-Payrasatre L, 141
- Rosing H *et al.* O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan, 587; *also* Nannan Panday VR, 665
- Roy JA. *See* Paridaens R, 29
- Roy P. *See* Boffetta P, 125
- Ruggeri A. *See* Mastronardi L, 581
- Rustum Y. *See* Harstrick A, 625
- Sabeur G. *See* Carles G, 209
- Safa AR. *See* Dolan ME, 437
- Safra T *et al.* Gemcitabine plus cisplatin combination given with amifostine (GAP) to heavily pretreated patients with gynecologic and peritoneal cancers: tolerance and activity in ovarian cancer, 511
- Sakakura C. *See* Hagiwara A, 287
- Sakamoto S *et al.* Additive effects of medroxyprogesterone acetate and 5-fluorouracil derivative on 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors, 351
- Sakata I. *See* Nakajima S, 539
- Sakiyama S. *See* Hiwasa T, 82
- Salmon SE. *See* Miller TP, 135
- Saravanan K. *See* Venkatesan PV, 449
- Sasaki S. *See* Takeda H, 715
- Sassa S. *See* Sakamoto S, 351
- Sata M. *See* Yamashita F, 399
- Satoh H. *See* Kim J, 689
- Scatizzi M. *See* Neri B, 599
- Scheidel P. *See* Carmichael J, 381
- Schellens JHM. *See* Nannan Panday VR, 665
- Schiebe ME *et al.* Mitomycin C-related hemolytic uremic syndrome in cancer patients, 433
- Schindler AE. *See* Carmichael J, 381
- Schleucher N. *See* Harstrick A, 625
- Schmidt DS. *See* Dwivedi C, 291
- Schmidt W. *See* Villena-Heinsen C, 557
- Schmitt C. *See* Allen M, 783
- Schot ME. *See* Herben VMM, 411
- Schuler D. *See* Paál K, 765
- Seeber S. *See* Harstrick A, 625; *also* Hartmann JT, 427; *also* Klaassen U, 203; *also* Klaassen U, 359
- Semb KA *et al.* Zilascorb^{(2)H}, a low-toxicity protein synthesis inhibitor that exhibits signs of anticancer activity in malignant melanoma, 797
- Serša G. *See* Čemažar M, 525
- Sert MB. *See* Abbas FM, 859
- Seymour RC. *See* Wurz GT, 181
- Sharma S. *See* Soda H, 327
- Shimamoto Y. *See* Fukushima M, 817
- Shimizu M. *See* Ashizawa T, 263
- Shin H-S. *See* Choi S-U, 157
- Shinoda H. *See* Sakamoto S, 351
- Shirasaka T. *See* Fukushima M, 817
- Shirasu M. *See* Hagiwara A, 287
- Shpitsky A. *See* Janss AJ, 641
- Siliani GM. *See* Neri B, 599
- Sin H-S. *See* Perchellet EM, 565
- Singh S *et al.* Acquisition of cellular resistance to 9-nitro-camptothecin correlates with suppression of transcription factor NF- κ B activation and potentiation of cytotoxicity by tumor necrosis factor in human histiocytic lymphoma U-937 cells, 703
- Singh SM. *See* Ranjan P, 333
- Sinnett D. *See* Côté S, 743
- Skovsgaard T. *See* Gehl J, 319
- Socinski MA *et al.* Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients, 611
- Soda H *et al.* Antiproliferative effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units, 327
- Sodhi A. *See* Ranjan P, 333
- Soe L. *See* Wurz GT, 181
- Sorich J. *See* Safra T, 511
- Sparatore F. *See* Cagnoli M, 603

Author index to volume 9

- Sparreboom A *et al.* Preclinical pharmacokinetics of paclitaxel and docetaxel, 1
- Stavropoulos G. *See* Liakopoulou-Kyriakides M, 175
- Steagall A. *See* Socinski MA, 611
- Stehlin JS. *See* Verschraegen CF, 36
- Story MD. *See* Breton C, 751
- Stoter G. *See* Boffetta P, 125; *also* Pronk LC, 759
- Strumberg D. *See* Klaassen U, 359
- Stubitz APN. *See* Stubitz KM, 45
- Stubitz KM *et al.* Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil[®]), 45
- Sutton L. *See* Janss AJ, 641
- Suzuki S. *See* Sakamoto S, 351
- Sweatman TW. *See* Lothstein L, 58
- Tabiaddon D. *See* Zaniboni A, 295
- Takahashi T. *See* Hagiwara A, 287; *also* Hagiwara A, 363; *also* Kanazawa J, 653
- Takeda H *et al.* Mechanisms of cytotoxic effects of heavy water (deuterium oxide: D₂O) on cancer cells, 715
- Takeda Y. *See* Kizu R, 167
- Takemura T. *See* Nakajima S, 539
- Tamaoki T. *See* Kanazawa J, 653
- Tamura K. *See* Takeda H, 715
- Tanaka M. *See* Yamashita F, 399
- Tanikawa K. *See* Yamashita F, 399
- ten Bokkel Huinink WW. *See* Herben VMM, 411; *also* Nannan Panday VR, 665
- Tendi E. *See* Messori A, 491
- ter Haar E. *See* Balachandran R, 67
- Thomas J. *See* Paridaens R, 675
- Thompson CB. *See* Dolan ME, 437
- Thulig CC. *See* Wolff JEA, 803
- Timony GA. *See* Soda H, 327
- Togawa T. *See* Hagiwara A, 287
- Tokita H. *See* Hiwasa T, 82
- Tomia E. *See* Paridaens R, 29
- Totsuka Y. *See* Matsushita K, 273
- Touw CR. *See* Uyl-de Groot CA, 835
- Trippoli S. *See* Messori A, 491; *also* Messori A, 909
- Tsuruoka T. *See* Kuramitsu Y, 88; *also* Kuramitsu Y, 739
- Tulliez J. *See* Gamet-Payrasatre L, 141
- Turcant A. *See* Gamelin E, 223
- Uchida J. *See* Fukushima M, 817
- Uegaki K. *See* Takeda H, 715
- Urso RG. *See* Prager TC, 515
- Uyl-de Groot CA *et al.* Economic evaluation of cancer treatments: methodological and practical issues, 835; *also* Buijt I, 889
- Vadhan-Raj S. *See* Benjapibal M, 577
- Valero V. *See* Benjapibal M, 577
- Van Daele D. *See* Gerard B, 301
- van den Bent MJ. *See* Pronk LC, 759
- van Dijk-Knijnenburg HCM. *See* Boffetta P, 125
- Van Glabbeke. *See* Paridaens R, 29
- van Oosterom AT. *See* Boffetta P, 125
- van Putten WJL. *See* Pronk LC, 759
- van Tellingen O. *See* Nannan Panday VR, 665; *also* Sparreboom A, 1
- Van Vreckem A. *See* Paridaens R, 29
- van Zomeren DM. *See* Rosing H, 587
- Vanhoefer U. *See* Harstrick A, 625
- Vannozzi MO. *See* Viale M, 457
- Varma D. *See* Kudelka AP, 405
- Varterasian M. *See* Mohammad RM, 149
- Vasuratna A *et al.* Prolonged remission of endometrial cancer with paclitaxel and carboplatin, 283; *also* Benjapibal M, 577; *also* Kudelka AP, 621
- Venkatachalam SR. *See* Rao KN, 727
- Venkatesan PV *et al.* Characterization of multidrug resistance and monitoring of tumor response by combined ³¹P and ¹H magnetic resonance spectroscopic analysis, 449
- Vermeiren P. *See* Paridaens R, 675
- Verschraegen CF *et al.* A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor, 36
- Verschraegen CF. *See* Benjapibal M, 577; *also* Kudelka AP, 405; *also* Kudelka AP, 621; *also* Vasuratna A, 283
- Verweij J. *See* Pronk LC, 759
- Viale M *et al.* Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines, 457; *also* Mandys V, 659
- Villena-Heinsen C *et al.* Human ovarian cancer xenografts in nude mice: chemotherapy trials with paclitaxel, cisplatin, vinorelbine and titanocene dichloride, 557
- Vinholes J. *See* Paridaens R, 29
- Von Hoff DD. *See* Davidson K, 635; *also* Soda H, 327
- Vrana J. *See* Mandys V, 659
- Wachowicz B. *See* Olas B, 473
- Wagenar DJTh. *See* Kamm YJL, 371
- Wait SH. Economic evaluation of endocrine therapy in the treatment of breast cancer, 849
- Wall N. *See* Mohammad RM, 149
- Wang H-M. *See* Chen J-S, 393
- Wang S-Y. *See* Lai Y-L, 77
- Weiderpass E. *See* Boffetta P, 125
- Welsh MJ. *See* Balachandran R, 67
- Weyhoben R. *See* Klaassen U, 203
- Wildiers J. *See* Paridaens R, 675
- Wilhelm LM. *See* Kurbacher CM, 51
- Wilke H. *See* Harstrick A, 625; *also* Klaassen U, 203; *also* Klaassen U, 359
- Wolff JEA *et al.* Polyoxoanions are cytotoxic to malignant glioma cells, 803
- Wootipoom V. *See* Vasuratna A, 283
- Wu T-Y. *See* Lai Y-L, 77
- Wurz GT *et al.* Intratumoral toremifene therapy and tissue distribution in the baboon, 181
- Yalowich JC. *See* Hasinoff BB, 465
- Yamamoto H. *See* Yamashita F, 399
- Yamamoto S. *See* Kizu R, 167
- Yamasaki J. *See* Hagiwara A, 287
- Yamashita F *et al.* A crossover study of oral administration of UFT in chronic liver disease: comparison of continuous and intermittent schedules, 399
- Yano Y. *See* Yamashita F, 399
- Yapp DTT *et al.* Cisplatin delivery by biodegradable polymer implant is superior to systemic delivery by osmotic pump or i.p. injection in tumor-bearing mice, 791
- Yelle L. *See* Krzakowski M, 593
- Yonekura R. *See* Fukushima M, 817
- Yoo S-E. *See* Choi S-U, 157
- Zaniboni A *et al.* Oral idarubicin and cyclophosphamide for metastatic breast cancer in elderly patients, 295
- Zhang Y-H. *See* Choi S-U, 255
- Zhao H. *See* Janss AJ, 641
- Zhao Y-P. *See* Zhu Z, 685
- Zhi J. *See* Kim J, 689
- Zhu J. *See* Yapp DTT, 791
- Zhu Z *et al.* Penetration kinetics of 5-fluorouracil into pancreatic fluid in post-pancreatoduodenectomy patients, 685
- Zou Y. *See* Prager TC, 515
- Zurlo MG. *See* Paridaens R, 675